These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 36522489)

  • 1. A proof-of-concept study on the genomic evolution of Sars-Cov-2 in molnupiravir-treated, paxlovid-treated and drug-naïve patients.
    Alteri C; Fox V; Scutari R; Burastero GJ; Volpi S; Faltoni M; Fini V; Granaglia A; Esperti S; Gallerani A; Costabile V; Fontana B; Franceschini E; Meschiari M; Campana A; Bernardi S; Villani A; Bernaschi P; Russo C; Guaraldi G; Mussini C; Perno CF
    Commun Biol; 2022 Dec; 5(1):1376. PubMed ID: 36522489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world effectiveness of molnupiravir, azvudine and paxlovid against mortality and viral clearance among hospitalized patients with COVID-19 infection during the omicron wave in China: A retrospective cohort study.
    Chen Y; Lin Y; Lu H; Wu X; Pan Y; Xia A; Pang L; Ye W; Xu F
    Diagn Microbiol Infect Dis; 2024 Aug; 109(4):116353. PubMed ID: 38776665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of molnupiravir on SARS-CoV-2 evolution in immunocompromised patients: a retrospective observational study.
    Fountain-Jones NM; Vanhaeften R; Williamson J; Maskell J; Chua IJ; Charleston M; Cooley L
    Lancet Microbe; 2024 May; 5(5):e452-e458. PubMed ID: 38527471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2.
    Wagoner J; Herring S; Hsiang TY; Ianevski A; Biering SB; Xu S; Hoffmann M; Pöhlmann S; Gale M; Aittokallio T; Schiffer JT; White JM; Polyak SJ
    Microbiol Spectr; 2022 Oct; 10(5):e0333122. PubMed ID: 36190406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic Surveillance of SARS-CoV-2 M
    Lee JT; Yang Q; Gribenko A; Perrin BS; Zhu Y; Cardin R; Liberator PA; Anderson AS; Hao L
    mBio; 2022 Aug; 13(4):e0086922. PubMed ID: 35862764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of RNA-Dependent RNA Polymerase Inhibitors, Molnupiravir and VV116, for Oral Treatment of COVID-19: A Meta-Analysis.
    Zheng Z; Zhou J; Song Y
    Iran J Med Sci; 2024 May; 49(5):275-285. PubMed ID: 38751873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes.
    Sanderson T; Hisner R; Donovan-Banfield I; Hartman H; Løchen A; Peacock TP; Ruis C
    Nature; 2023 Nov; 623(7987):594-600. PubMed ID: 37748513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis.
    Wen W; Chen C; Tang J; Wang C; Zhou M; Cheng Y; Zhou X; Wu Q; Zhang X; Feng Z; Wang M; Mao Q
    Ann Med; 2022 Dec; 54(1):516-523. PubMed ID: 35118917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial.
    Donovan-Banfield I; Penrice-Randal R; Goldswain H; Rzeszutek AM; Pilgrim J; Bullock K; Saunders G; Northey J; Dong X; Ryan Y; Reynolds H; Tetlow M; Walker LE; FitzGerald R; Hale C; Lyon R; Woods C; Ahmad S; Hadjiyiannakis D; Periselneris J; Knox E; Middleton C; Lavelle-Langham L; Shaw V; Greenhalf W; Edwards T; Lalloo DG; Edwards CJ; Darby AC; Carroll MW; Griffiths G; Khoo SH; Hiscox JA; Fletcher T
    Nat Commun; 2022 Nov; 13(1):7284. PubMed ID: 36435798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editorial: Rebound COVID-19 and Cessation of Antiviral Treatment for SARS-CoV-2 with Paxlovid and Molnupiravir.
    Parums DV
    Med Sci Monit; 2022 Oct; 28():e938532. PubMed ID: 36181334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interactions of the Anti-SARS-CoV-2 Agents Molnupiravir and Nirmatrelvir/Paxlovid with Human Drug Transporters.
    Bakos É; Temesszentandrási-Ambrus C; Özvegy-Laczka C; Gáborik Z; Sarkadi B; Telbisz Á
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37510996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs.
    Saravolatz LD; Depcinski S; Sharma M
    Clin Infect Dis; 2023 Jan; 76(1):165-171. PubMed ID: 35245942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase.
    Zhao J; Guo S; Yi D; Li Q; Ma L; Zhang Y; Wang J; Li X; Guo F; Lin R; Liang C; Liu Z; Cen S
    Antiviral Res; 2021 Jun; 190():105078. PubMed ID: 33894278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pandemic COVID-19, an update of current status and new therapeutic strategies.
    Vitiello A; La Porta R; Trama U; Ferrara F; Zovi A; Auti AM; Di Domenico M; Boccellino M
    Naunyn Schmiedebergs Arch Pharmacol; 2022 Oct; 395(10):1159-1165. PubMed ID: 35779085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis.
    Kabinger F; Stiller C; Schmitzová J; Dienemann C; Kokic G; Hillen HS; Höbartner C; Cramer P
    Nat Struct Mol Biol; 2021 Sep; 28(9):740-746. PubMed ID: 34381216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial.
    Schilling WHK; Jittamala P; Watson JA; Boyd S; Luvira V; Siripoon T; Ngamprasertchai T; Batty EM; Cruz C; Callery JJ; Singh S; Saroj M; Kruabkontho V; Ngernseng T; Tanglakmankhong N; Tubprasert J; Abdad MY; Madmanee W; Kouhathong J; Suwannasin K; Pagornrat W; Piaraksa N; Hanboonkunupakarn P; Hanboonkunupakarn B; Poovorawan K; Potaporn M; Srisubat A; Loharjun B; Taylor WRJ; Chotivanich V; Chotivanich K; Imwong M; Pukrittayakamee S; Dondorp AM; Day NPJ; Teixeira MM; Piyaphanee W; Phumratanaprapin W; White NJ;
    Lancet Infect Dis; 2024 Jan; 24(1):36-45. PubMed ID: 37778363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of late-onset antiviral treatment in immunocompromised hosts with persistent SARS-CoV-2 infection.
    Lieber CM; Kang H-J; Sobolik EB; Sticher ZM; Ngo VL; Gewirtz AT; Kolykhalov AA; Natchus MG; Greninger AL; Suthar MS; Plemper RK
    J Virol; 2024 Sep; 98(9):e0090524. PubMed ID: 39207133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decoding molnupiravir-induced mutagenesis in SARS-CoV-2.
    Menéndez-Arias L
    J Biol Chem; 2021 Jul; 297(1):100867. PubMed ID: 34118236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Viral target and metabolism-based rationale for combined use of recently authorized small molecule COVID-19 medicines: Molnupiravir, nirmatrelvir, and remdesivir.
    Yan D; Yan B
    Fundam Clin Pharmacol; 2023 Aug; 37(4):726-738. PubMed ID: 36931725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Systematic Review of the Global Intervention for SARS-CoV-2 Combating: From Drugs Repurposing to Molnupiravir Approval.
    Ashour NA; Abo Elmaaty A; Sarhan AA; Elkaeed EB; Moussa AM; Erfan IA; Al-Karmalawy AA
    Drug Des Devel Ther; 2022; 16():685-715. PubMed ID: 35321497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.